A possible association between aprotinin and improved survival after radical surgery for mesothelioma

Cancer

Volumn 115, Issue 4, 2009, Pages 833-841

  Norman, Peter H ^a,c   Thall, Peter F ^a   Purugganan, Ronaldo V ^a   Riedel, Bernhard J C J ^a   Thakar, Dilip R ^a   Rice, David C ^a   Huynh, Lisa ^a   Qiao, Wei ^a   Wen, Sijin ^a   Roy Smythe, W ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Aprotinin; Bayesian analysis; Log normal regression model; Mesothelioma; Pneumonectomy; Serine protease inhibitor; Surgical blood loss

Indexed keywords

APROTININ; PLACEBO;

ADULT; AGED; ARTICLE; BAYES THEOREM; BLEEDING; BLOOD TRANSFUSION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DECORTICATION; DOUBLE BLIND PROCEDURE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOADING DRUG DOSE; LUNG RESECTION; LYMPH NODE METASTASIS; MALE; MESOTHELIOMA; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURGICAL MORTALITY; THORACOTOMY; TREATMENT OUTCOME;

AGED; APROTININ; BLOOD LOSS, SURGICAL; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HEMOSTATICS; HUMANS; LYMPHATIC METASTASIS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PNEUMONECTOMY; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 60849124224     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24108     Document Type: Article

References (33)

1. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2:1289-1291.
2. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 1989;97:364-372.
3. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 1994;107:554-561.
4. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
5. Lentschener C, Benhamou D, Mercier FJ, et al. Aprotinin reduces blood loss in patients undergoing elective liver resection. Anesth Analg. 1997;84:875-881.
6. Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovitch J, d'Athis F. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology. 1998;88:50-57.
7. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor I. J Thorac Cardiovasc Surg. 2000;120:370-378.
8. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet. 2004;364:1183-1185.
9. Zacharski L. Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett. 2002;186:1.
10. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
11. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemo- ther Rep. 1966;60:163-170.
13. Randles RH, Wolfe DA. Introduction to the Theory of Non- parametric Statistics. New York: John Wiley & Sons; 1979.
14. Therneau TM, Grambsch. PA. Modeling Survival Data. New York: Springer; 2000.
15. Ibrahim JG, Chen M-H, Sinha D. Bayesian Survival Analysis. New York: Springer; 2001.
16. Venables WN, Ripley BD. Modern Applied Statistics With S. 4th ed. New York: Springer; 2002.
17. Imperial College and Medical Research Council. WinBugs Version 1.4. London, UK: Imperial College and Medical Research Council; 2003.
18. US Food and Drug Administration. FDA revises labeling for Trasylol (aprotinin injection) to strengthen safety warnings and limit usage of drug to specific situations [press release]. FDA News. 2006;P06-P203.
19. Bakaaen F, Rice D, Correa AM, et al. Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications. Ann Thorac Surg. 2007;84:986-987.
20. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644.
21. Latner AL, Longstaff E, Pradhan K. Inhibition of malignant cell invasion in vitro by a proteinase inhibitor. Br J Cancer. 1973;27:460-464.
22. Latner AL, Longstaff E. Antitumor activity of aprotinin. Br JCancer. 1974;30:60-67.
23. Vaporciyan AA, Putnam JB, Smythe WR. The potential role of aprotinin in the perioperative management of malignant tumors. J Am Coll Surg. 2004;198:266-278.
24. Mikhalkin IA, Iashvili ZG, Bykov VL. Thermoradiotherapy combined with a proteolysis inhibitor (Contrical) in the treatment of head and neck cancer. Oncology. 1993;50:344-347.
25. Lentschener C, Li H, Franco D, et al. Intraoperatively administered aprotinin and survival after elective liver resection for colorectal cancer metastases. A preliminary study. Fibrinolys Proteolys. 1999;13:39-45.
26. Zimbler N, Wall CN, Townsend ER, Royston D. Use of intra-operative high dose aprotinin may be associated with improved longer term outcome following esophagectomy for cancer [Abstract A1187]. Presented at the Annual Meeting of the American Society of Anesthesiologists, Orlando, Florida, October 12-16, 2002.
27. Hayashi I, Amano H, Yoshida S, et al. Suppressed angiogenesis in kininogen-deficiencies. Lab Invest. 2002;82:871-880.
28. Ploplis VA, Tipton H, Menchen H, Castellino FJ. A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in Apc(Min/+) mice. J Pathol. 2007;213:266-274.
29. Uchima Y, Sawada T, Hirakawa K. Action of antiproteases on pancreatic cancer cells. JOP. 2007;8(4 suppl):479-487.
30. Perkins RC, Broaddus VC, Shetty S, Hamilton S, Idell S. Asbestos up-regulates expression of the urokinase-type plasminogen activator receptor on mesothelial cells. Am J Respir Cell Mol Biol. 1999;21:637-646.
31. Heidtmann HH, Hofmann M, Jacob E, Erbil C, Havemann K, Schwartz-Albiez R. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. Cancer Res. 1989;49(24 pt 1):6960-6965.
32. Treasure T, Tan C, Lang-Lazdunski L, Waller D. The MARS trial: mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg. 2006;5:58-59.
33. Ferguson TB. Aprotinin-are there lessons learned [editorial]? JAMA. 2007;297:527-529.